CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 251 enrolled
Drug / intervention
Acetylcystein +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00463749
NCT00463749Phase 3Completed
CompareCT.gov

Trial to Compare Infarct Size and Occurrence of Contrast Dye Induced Nephropathy in Patients With Primary Percutaneous PCI in STEMI

University of Leipzig·interventional·Posted Apr 20, 2007·Updated Jul 8, 2008

In Brief

A Phase 3 clinical trial evaluating Acetylcystein and Placebo for Myocardial Infarction. Completed, enrolled 251 participants across 1 site.

Detailed Summary

Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration. In primary percutaneous intervention for infarction hydration is not possible. Therefore Acetylcystein might prevent contrast dye induced nephropathy. Furthermore, it might reduce infarct size as a result of its antioxidant properties. Clinical trials are missing so far examining the effects of Acetylcystein on nephropathy and infarct size.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 20, 2007
Enrollment StartDec 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 19.2 years ago

Interventions

Acetylcysteindrug

high-dose N-Acetylcystein during PCI and for 2/day for 2 days

Placebodrug

NaCl as placebo